BR112015011213A2 - Composto, composição farmacêutica, método de prevenção ou tratamento de um distúrbio ou doença de controle respiratório em um indivíduo, método de prevenção de desestabilização ou de estabilização do ritmo respiratório em um indivíduo, método de preparação de o,n-dimetil-n-[4-(n-propilamina)-6-(prop-2-inilamina)-[1,3,5]triazin-2-il]-hidroxilamina, e composição. - Google Patents

Composto, composição farmacêutica, método de prevenção ou tratamento de um distúrbio ou doença de controle respiratório em um indivíduo, método de prevenção de desestabilização ou de estabilização do ritmo respiratório em um indivíduo, método de preparação de o,n-dimetil-n-[4-(n-propilamina)-6-(prop-2-inilamina)-[1,3,5]triazin-2-il]-hidroxilamina, e composição.

Info

Publication number
BR112015011213A2
BR112015011213A2 BR112015011213A BR112015011213A BR112015011213A2 BR 112015011213 A2 BR112015011213 A2 BR 112015011213A2 BR 112015011213 A BR112015011213 A BR 112015011213A BR 112015011213 A BR112015011213 A BR 112015011213A BR 112015011213 A2 BR112015011213 A2 BR 112015011213A2
Authority
BR
Brazil
Prior art keywords
individual
prevention
respiratory
composition
disorder
Prior art date
Application number
BR112015011213A
Other languages
English (en)
Inventor
C Mannion James
L Dax Scott
Francis Golder John
Duncan Macintyre Euan
Mcleod James
Ozola Vita
Suna Edgars
Shubin Kirill
James Mencel Joseph
x peng Sean
Original Assignee
Galleon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galleon Pharmaceuticals Inc filed Critical Galleon Pharmaceuticals Inc
Publication of BR112015011213A2 publication Critical patent/BR112015011213A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/54—Three nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/54—Three nitrogen atoms
    • C07D251/70—Other substituted melamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

COMPOSTO, COMPOSIÇÃO FARMACÊUTICA, MÉTODO DE PREVENÇÃO OU TRATAMENTO DE UM DISTÚRBIO OU DOENÇA DE CONTROLE RESPIRATÓRIO EM UM· INDIVÍDUO, MÉTODO DE PREVENÇÃO DE/DESESTABILIZAÇÃO OU DE ESTABILIZAÇÃO DO RITMO RESPIRATÓRIO EM UM INDIVÍDUO, MÉTODO DE PREPARAÇÃO DE O,N-DIMETIL-N:[4-(NPRO Pl LAMI NA)-6-{P RO P-2-1 NI LAM I NA)-[1,3 ,S]TRIAZI N-2-1 L]-HIDROXILAMINA, E COMPOSIÇÃO. A presente invenção trata de composições que são úteis na prevenção e/ou tratamento de doenças ou distúrbios de controle respiratório em um indivíduo que precisam destas. A presente invenção também trata de um método de prevenção e/ou tratamento de uma doença ou distúrbio respiratório em um indivíduo que precisa destes, compreendendo a administração, ao indivíduo, de uma quantidade terapeuticamente eficaz de uma composição da invenção. A presente invenção ainda trata de um método de prevenção de desestabilização ou de estabilização de ritmo respiratório em um indivíduo que precisa disso, compreendendo administração, ao indivíduo, de uma quantidade terapeuticamente eficaz de uma composição da invenção.
BR112015011213A 2012-11-15 2013-11-14 Composto, composição farmacêutica, método de prevenção ou tratamento de um distúrbio ou doença de controle respiratório em um indivíduo, método de prevenção de desestabilização ou de estabilização do ritmo respiratório em um indivíduo, método de preparação de o,n-dimetil-n-[4-(n-propilamina)-6-(prop-2-inilamina)-[1,3,5]triazin-2-il]-hidroxilamina, e composição. BR112015011213A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261726823P 2012-11-15 2012-11-15
US201361783451P 2013-03-14 2013-03-14
PCT/US2013/070160 WO2014078575A2 (en) 2012-11-15 2013-11-14 Novel orally bioavailable breathing control modulating compounds, and methods of using same

Publications (1)

Publication Number Publication Date
BR112015011213A2 true BR112015011213A2 (pt) 2017-08-29

Family

ID=50731822

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015011213A BR112015011213A2 (pt) 2012-11-15 2013-11-14 Composto, composição farmacêutica, método de prevenção ou tratamento de um distúrbio ou doença de controle respiratório em um indivíduo, método de prevenção de desestabilização ou de estabilização do ritmo respiratório em um indivíduo, método de preparação de o,n-dimetil-n-[4-(n-propilamina)-6-(prop-2-inilamina)-[1,3,5]triazin-2-il]-hidroxilamina, e composição.

Country Status (12)

Country Link
US (1) US20150291597A1 (pt)
EP (1) EP2920155A2 (pt)
JP (1) JP2015537032A (pt)
KR (1) KR20150082633A (pt)
CN (1) CN104918923A (pt)
AU (1) AU2013344653A1 (pt)
BR (1) BR112015011213A2 (pt)
CA (1) CA2891342A1 (pt)
EA (1) EA201590933A1 (pt)
MX (1) MX2015006120A (pt)
SG (1) SG11201503505QA (pt)
WO (1) WO2014078575A2 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013267570A1 (en) * 2012-05-29 2014-12-18 Galleon Pharmaceuticals, Inc. Novel compounds and compositions for treatment of breathing control disorders or diseases
US9549909B2 (en) 2013-05-03 2017-01-24 The Katholieke Universiteit Leuven Method for the treatment of dravet syndrome
ES2925951T3 (es) 2015-07-22 2022-10-20 John Hsu Composición que comprende un agente terapéutico y un estimulante respiratorio y métodos para su uso
LT3393655T (lt) 2015-12-22 2021-03-25 Zogenix International Limited Fenfluramino kompozicijos ir jų paruošimo būdai
EP3393470B1 (en) 2015-12-22 2021-01-20 Zogenix International Limited Metabolism resistant fenfluramine analogs and methods of using the same
US20180055789A1 (en) 2016-08-24 2018-03-01 Zogenix International Limited Formulation for inhibiting formation of 5-ht2b agonists and methods of using same
US10682317B2 (en) 2017-09-26 2020-06-16 Zogenix International Limited Ketogenic diet compatible fenfluramine formulation
WO2019216919A1 (en) 2018-05-11 2019-11-14 Zogenix International Limited Compositions and methods for treating seizure-induced sudden death
WO2019241005A1 (en) 2018-06-14 2019-12-19 Zogenix International Limited Compositions and methods for treating respiratory depression with fenfluramine
US11612574B2 (en) 2020-07-17 2023-03-28 Zogenix International Limited Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
CA3236586A1 (en) * 2021-11-02 2023-05-11 Joseph Pergolizzi Methods of treating respiratory depression modulated by a non-opioid agent
AU2022426492A1 (en) * 2021-12-27 2024-07-18 Enalare Therapeutics Inc. Respiratory stimulant parenteral formulations

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9106170D0 (en) * 1991-03-22 1991-05-08 Jarman Michael New compounds for use in the treatment of cancer
EP2078715A4 (en) * 2006-10-30 2010-04-14 Nippon Steel Chemical Co PROTON-CONNECTING CONNECTION AND PROTON-CONDUCTIVE POLYMER
DE102007025451B4 (de) * 2007-05-31 2013-03-28 Ami Agrolinz Melamine International Gmbh Triazinderivate
CN103347866B (zh) * 2010-11-29 2016-05-18 加林制药公司 作为治疗呼吸控制不适或疾病的呼吸兴奋剂的新化合物
WO2012166909A1 (en) * 2011-06-03 2012-12-06 Galleon Pharmaceuticals, Inc. Compositions and methods for treating breathing control disorders or diseases

Also Published As

Publication number Publication date
US20150291597A1 (en) 2015-10-15
WO2014078575A2 (en) 2014-05-22
AU2013344653A1 (en) 2015-05-21
KR20150082633A (ko) 2015-07-15
EP2920155A2 (en) 2015-09-23
JP2015537032A (ja) 2015-12-24
WO2014078575A3 (en) 2014-10-16
EA201590933A1 (ru) 2015-11-30
MX2015006120A (es) 2016-02-05
SG11201503505QA (en) 2015-06-29
CN104918923A (zh) 2015-09-16
CA2891342A1 (en) 2014-05-22

Similar Documents

Publication Publication Date Title
BR112015011213A2 (pt) Composto, composição farmacêutica, método de prevenção ou tratamento de um distúrbio ou doença de controle respiratório em um indivíduo, método de prevenção de desestabilização ou de estabilização do ritmo respiratório em um indivíduo, método de preparação de o,n-dimetil-n-[4-(n-propilamina)-6-(prop-2-inilamina)-[1,3,5]triazin-2-il]-hidroxilamina, e composição.
BR112019008431A2 (pt) aplicação de (s)-norcetamina e sal da mesma como fármaco
BR112017003546A2 (pt) amidas heterocíclicas como inibidores de rip1 quinase como medicamentos
BR112015005117A2 (pt) métodos de tratamento da doença de alzheimer e suas composições farmacêuticas
BR112013018920A2 (pt) composições de nanopartículas, formulações destas e seus usos
MX355330B (es) Formas cristalinas de compuestos terapeuticos y sus usos.
BR112015016466A2 (pt) método para o tratamento de câncer baseado no estado de mutação de k-ras
BR112013013429A2 (pt) composição, método de prevenção ou tratamento de distúrbio ou doença de controle da respiração, e, método de prevenção de desestabilização ou estabilização do ritmo respiratório
BR112013027034A8 (pt) "compostos para o tratamento de transtornos neuropsiquiátricos."
WO2016090024A3 (en) Combination therapy for treatment of cancer
BR112015022650A2 (pt) inibidores de cinase induzível por sal macrocíclico
BR112015017775A2 (pt) enzima cistationina beta-sintase para o tratamento de homocistinúria
BR112013027241A2 (pt) "composto inibidor de rock, composição que o compreende e seus usos"
AU2018253538A1 (en) Levodopa formulations for rapid relief of parkinson's disease
BR112013027486A2 (pt) combinação de um inibidor de fosfatidilinositol-3-cinase (pi3k) e um inibidor de mtor
BR112014005538A2 (pt) composições aquosas compreendendo arbecacina
BR112015028516A2 (pt) tratamento ou prevenção de distúrbios neurodegenerativos com o uso de mentol, linalol e/ou icilina
BR112014028446A2 (pt) composto isolado, composição farmacêutica, método de tratamento ou prevenção de pelo menos um de doenças, distúrbios ou condições seguintes, e, método de tratamento ou prevenção de um distúrbio de ritmo circadiano ou distúrbio com um componente circadiano em um indivíduo
BR112014032264A8 (pt) Composiçâo para tratamento ou prevençâo de doenças relacionadas á permeabilidade vascular, contendo imatinibe ou um sal farmaceuticamente aceitável respectivo como ingrediente ativo
EA201591693A1 (ru) Новые соединения, модулирующие контроль над дыханием, и способы их применения
BR112015007095A2 (pt) derivados de di-hidro-6-azafenaleno para o tratamento de doenças do snc, oncológicas e distúrbios relacionados
WO2013181217A3 (en) Novel compounds and compositions for treatment of breathing control disorders or diseases
BR112014007684A2 (pt) tratamento da rinite
BR112018067663A2 (pt) compostos derivados de sulfamato, processos para preparação dos mesmos e seus usos
MX2013011561A (es) Compuestos de benzodioxepina y benzodioxina que interactuan con la proteina reguladora de glucocinasa para el tratamiento de diabetes.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]